What is HIMS Stock? An In-Depth Look at Hims & Hers Health — The Complete Guide to HIMS Stock

HIMS stock is one of the most-watched equities in global markets in 2024–2025, with a price surge of over 2,000% from its all-time low followed by an equally dramatic correction. Many investors still wonder exactly what HIMS stock is, what the company actually does, and why it attracts so much attention. This guide covers everything you need to know — from the business fundamentals to the key factors that drive HIMS stock price movements.

What Is HIMS Stock? Meet Hims & Hers Health Inc.

HIMS is the ticker symbol for Hims & Hers Health, Inc., a company listed on the New York Stock Exchange (NYSE). The business was founded in 2017 in San Francisco, California by Andrew Dudum and co-founders.

Hims & Hers Health is a telehealth and consumer health company that connects patients with licensed physicians online and delivers prescription medications directly to their door. The company focuses on health categories where people often feel too embarrassed to visit a traditional doctor — including hair loss, sexual health, skin conditions, mental health, and weight management.

What Does HIMS Stock Do? The Core Business of Hims & Hers

The simplest way to think about Hims & Hers is as a full-service online clinic — one that combines the doctor consultation, the prescription, and the pharmacy delivery into a single seamless experience via a website or mobile app. The core business model is a monthly subscription: customers pay a recurring fee and receive their medications or health products automatically delivered to their home each month.

Current product and service categories at Hims & Hers include the following.

• Weight Management — the top revenue driver today, including GLP-1 medications such as Semaglutide and Novo Nordisk’s branded Ozempic and Wegovy, plus other weight loss treatments
• Hair Loss — for both men and women, the original product category that launched the company, featuring Finasteride and Minoxidil
• Men’s Sexual Health — ED medications including Sildenafil (generic Viagra) and Tadalafil (generic Cialis)
• Mental Health — online therapy services and psychiatric medication management
• Skincare — acne treatments, anti-aging creams, and other dermatology products
• Women’s Health — including perimenopause and menopause treatments launched in 2025

What sets Hims & Hers apart from a traditional clinic is that the company removes the barriers to care — no appointment needed, no travel, and pricing that is more accessible than conventional healthcare. This frictionless model has fueled rapid subscriber growth.

How Did HIMS Stock Enter the Market

Hims & Hers Health did not go public through a traditional IPO. Instead, it entered the NYSE in January 2021 via a merger with a SPAC (Special Purpose Acquisition Company) called Oaktree Acquisition Corp. Shares started trading at around $10. The stock then endured a brutal decline through 2022 before recovering and surging to an all-time high in 2025.

HIMS Stock Price — History and Key Milestones

The HIMS stock price history is a textbook example of a high-beta growth stock that swings violently in response to news and business developments.

The table shows just how volatile HIMS stock can be. From its all-time low of $2.72 the stock climbed to $72.98 — a gain of more than 2,500% — before falling sharply again. Investors who understand the key drivers behind these moves are better equipped to navigate the volatility.

Why Did HIMS Stock Surge in 2024–2025

The main factors that pushed HIMS stock sharply higher during 2024–2025 were as follows.

• The GLP-1 and Semaglutide boom — when weight loss drugs Ozempic and Wegovy faced shortages in the US, the FDA allowed compounders to produce Compounded Semaglutide. Hims & Hers became one of the largest providers, and revenue from this segment exploded
• Revenue growth well above expectations — full-year 2025 revenue reached $2.35 billion, up 59% year over year, beating analyst forecasts
• Subscriber growth — Q3 2025 subscribers reached 2.5 million, up 21% year over year
• First-ever net profit — the company posted net income of $128 million in 2025, its first profitable year in history

Why Did HIMS Stock Crash in Early 2026

After reaching the all-time high of $72.98 in February 2025, HIMS stock fell sharply to $13.74 in February 2026. The main reasons were the following.

• FDA removed Semaglutide from the shortage list — once the FDA declared the drug no longer in shortage, Hims & Hers lost the legal ability to compound Semaglutide, eliminating a major revenue stream
• Regulatory uncertainty — investors worried the company could not replace that lost revenue fast enough
• Intensifying competition — rivals including Ro Health, Noom, and other digital health platforms moved aggressively to capture market share

What Does HIMS Stock Do? Revenue Breakdown

To fully understand what HIMS stock does, it helps to look at where the money actually comes from.

The core strength of the Hims & Hers business model is that the vast majority of revenue is recurring subscription income. As the subscriber base grows, cost per customer falls and margins improve over time — a dynamic that makes the business increasingly capital-efficient at scale.

Key Financial Figures for HIMS

Factors That Drive HIMS Stock Price

Understanding what moves HIMS stock price helps investors make more informed decisions. The main drivers fall into four categories.

1. FDA Policy and Regulation

The single most important driver for HIMS over the past two years has been FDA decisions on GLP-1 medications. When the FDA listed Semaglutide as a shortage drug, Hims & Hers benefited enormously. When the FDA removed it from the shortage list, the stock crashed. Investors must track FDA news closely when holding this stock.

2. Quarterly Earnings Results

Every time the company reports earnings, the stock tends to move sharply in either direction. The figures investors watch most closely are total revenue, subscriber growth, and Adjusted EBITDA.

3. Competition in the Telehealth Market

The telehealth market is becoming increasingly competitive, with focused health rivals such as Ro Health, Noom, and Teladoc, as well as large platforms like Amazon Pharmacy and CVS Health that could enter the direct-to-consumer prescription market.

4. Strategic Partnerships

Deals with major pharmaceutical companies have a significant impact on the stock. The announcement of a partnership with Novo Nordisk to distribute branded GLP-1 drugs in March 2026 led Goldman Sachs and JP Morgan to upgrade the stock to Overweight, triggering a meaningful recovery in the share price.

HIMS vs Telehealth Competitors

Pros and Cons of Investing in HIMS Stock

Pros of HIMS Stock

• Exceptional revenue growth — revenue rose 59% in 2025 with a long-term target of $6.5 billion by 2030
• Achieved profitability — net income of $128 million in 2025 for the first time, addressing concerns about cash burn
• Subscription model creates predictable recurring revenue — subscribers tend to stay because they need ongoing medication refills
• Telehealth is a long-term secular trend — consumer appetite for online healthcare accelerated after COVID-19 and shows no sign of reversing
• Strong brand recognition — both the Hims (men) and Hers (women) brands are well recognized in the US market

Cons and Risks of HIMS Stock

• High regulatory risk — the telehealth business depends heavily on FDA policy and healthcare legislation that can change without warning
• Extreme share price volatility — with a beta of 1.84, HIMS moves nearly twice as much as the broader market
• Intensifying competition — new entrants from both startups and large incumbents are eroding market share
• No clear economic moat yet — Morningstar has not assigned the company a moat rating
• Over-reliance on GLP-1 revenue — FDA policy changes on weight-loss drugs have an outsized impact on business results

HIMS Stock Outlook and Future Targets

2026 and 2030 Financial Targets

The company has published clear financial targets.

• 2026 — quarterly revenue of $530–$550 million and Adjusted EBITDA margin of 12–14%
• 2030 — annual revenue of at least $6.5 billion and Adjusted EBITDA of at least $1.3 billion

New Strategy After the FDA Semaglutide Rule Change

After losing the ability to compound Semaglutide, Hims & Hers has laid out a new strategic direction.

• Partnership with Novo Nordisk to distribute branded Wegovy and Ozempic officially
• Expansion into Eli Lilly’s Zepbound, despite its high retail price of $1,899 per month
• Launch of perimenopause and menopause treatment services to attract a new female subscriber base
• International expansion into new markets
• Investment in AI and data analytics to deliver more personalized care at scale

Analyst Views on HIMS Stock Price

Following the Novo Nordisk partnership announcement in March 2026, several major financial institutions updated their ratings.

• Goldman Sachs upgraded from Neutral to Overweight
• JP Morgan upgraded from Neutral to Overweight
• Analysts noted that legal risk from the compounding business has significantly decreased after the deal
• Some firms view HIMS as a potential acquisition target for a company such as CVS Health or Apple

Disclaimer: Analyst opinions are not a guarantee of returns. Past stock price performance does not guarantee future results. Always conduct your own research before making any investment decision.

How to Invest in HIMS Stock

Investors interested in HIMS stock can access it through several channels.

Ways to Buy HIMS Stock

Key Considerations Before Investing

• Capital gains from foreign stocks may be subject to local tax reporting requirements in your country of residence
• US dividend withholding tax of up to 30% applies to non-US investors, though HIMS currently pays no dividend
• Currency risk between USD and your local currency can affect real returns
• Consult a qualified financial or tax adviser before investing in foreign equities

Risk Warning: Investing in stocks involves risk. You may lose all of your invested capital. This content is for general information purposes only and does not constitute financial advice. Always research thoroughly and consult a qualified professional before making any investment decision.

Summary — What Is HIMS Stock and Is It Worth Watching

HIMS stock — Hims & Hers Health Inc. — is a fast-growing telehealth company built on a subscription model that makes healthcare more accessible for conditions people are often too embarrassed to discuss openly. The business generated $2.35 billion in revenue in 2025 and achieved net profitability for the first time. However, the stock price remains highly volatile and closely tied to FDA decisions and competitive dynamics.

Key things to remember about HIMS stock.

• HIMS is the NYSE ticker for Hims & Hers Health Inc.
• The core business is telehealth plus subscription home delivery of prescription medications
• Main products include GLP-1 weight loss drugs, hair loss medication, and ED treatments
• The all-time high was $72.98 in February 2025
• The primary risks are FDA policy changes and intensifying telehealth competition
• The 2030 revenue target is $6.5 billion

Frequently Asked Questions About HIMS Stock

What is HIMS stock

HIMS is the NYSE ticker symbol for Hims & Hers Health Inc., a US-based telehealth company that connects patients with licensed physicians online and delivers prescription medications to their homes. The company focuses on health categories that carry social stigma, such as weight management, hair loss, and sexual health.

What does HIMS stock do

Hims & Hers operates a direct-to-consumer telehealth platform in the United States. Users consult with doctors online and receive prescription medications on a monthly subscription basis. Current flagship products include GLP-1 weight loss drugs (Semaglutide, Wegovy, Ozempic), hair loss treatments, ED medications, mental health services, and skincare.

What is the HIMS stock price today

HIMS stock price changes every trading day. As of May 2026, HIMS was trading at approximately $25–$30 per share, well below its all-time high of $72.98 reached in February 2025. For the current price check Google Finance, Yahoo Finance, or TradingView.

Why did HIMS stock go up so much in 2024–2025

HIMS stock surged in 2024–2025 primarily because of the GLP-1 shortage boom, where the FDA allowed companies to produce compounded versions of Semaglutide. Hims & Hers became a major supplier, driving explosive revenue growth. The stock was also boosted by the company reporting its first-ever net profit in 2025.

Why did HIMS stock fall in 2026

HIMS stock dropped sharply in early 2026 after the FDA removed Semaglutide from its drug shortage list. This ended the legal basis for compounding the drug at scale, which had been a central revenue driver. Investors sold the stock on fears that the company could not replace that income quickly, pushing shares from over $70 down to $13.74 in February 2026.

What type of investor is HIMS stock suited for

HIMS stock is suited for investors with a high risk tolerance and a long-term investment horizon who believe in the secular growth of telehealth. It is not suitable for investors seeking stability or dividend income. The company currently pays no dividend, and the stock is among the more volatile equities on the NYSE.

Does HIMS stock pay a dividend

No. Hims & Hers Health does not pay a dividend. The company reinvests its profits into growth. Returns for investors come entirely from capital appreciation — the difference between the purchase price and the sale price.

Can international investors buy HIMS stock

Yes. International investors can purchase HIMS stock through brokers that provide access to US markets, such as Interactive Brokers, eToro, or Saxo Bank. Be aware of currency conversion costs, local tax reporting obligations on foreign investment gains, and any applicable withholding taxes. Consult a financial or tax adviser before investing.

Risk Warning: The content in this article is for general informational purposes only. It does not constitute financial or investment advice. Investing in stocks involves risk and you may lose all of your capital. Always conduct thorough research and consult a qualified professional before making any investment decision.

You might also be interested in:
What Is PNL in Trading?

Best Forex Brokers

What Is Margin in Trading?